You didn’t need to be in the room to access the insights
The antibody-drug conjugate landscape is rapidly expanding beyond traditional constructs, creating a more diverse ecosystem of next-generation approaches. Presented at World ADC San Diego 2026 by Yu-Shin Hsu, Senior Research Analyst at Beacon Intelligence, this presentation examines the technologies, targets and developers shaping this next wave of innovation.
What the slides cover:
What the presentation covers:
- Multispecific ADCs: The expanding bispecific and trispecific landscape, including drug status, clinical activity, target combinations, key indications and the global distribution of developers.
- Antibody-oligonucleotide conjugates: Pipeline growth, new clinical entries, target and disease trends, leading developers, and key regulatory milestones.
- Degrader-antibody conjugates: The emerging DAC pipeline, including drug status, target selection, investigational indications and the developers advancing the modality.
- Dual-payload ADCs: The increasing clinical momentum behind DP-ADCs, with analysis of targets, payload mechanism combinations, disease indications, key players and recent clinical entries.
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
